Different from other cancer types, relapse events in patients with estrogen receptor–positive (ER+) breast cancer do not decline with time (7), do not spike at the end of adjuvant ETs (8), nor are significantly influenced by the size of the tumor (9, 10). Here, ESR1 is linked to breast cancer.